Financial results for the period ended Jun 30, 2026
As filed · Hester Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
What happened
FactHester Biosciences Limited's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 during a meeting held on 30 July 2026. The company will publish an extract of the results in the newspaper as required by regulations. The filing includes the approved financial results and limited review reports.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
DelayedPreparations for the Avian Influenza vaccine launch remain on track, with the expected roll-out in the second quarter of FY26 poised to further strengthen our portfolio.
we remain confident in achieving breakeven within the next two years, with further profitability gains beyond that.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- we remain confident in achieving breakeven within the next two years, with further profitability gains beyond (management committed by FY27)
- Our Fill-Finish facility is on track to be operational by Q2 FY26, and the BSL-3 facility awaits final adminis (management committed by Q2 FY26)
Evidence
- Hester Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · FY25
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%